Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase
作者:Martin Krátký、Eva Novotná、Jiřina Stolaříková、Markéta Švarcová、Jarmila Vinšová
DOI:10.1016/j.ejps.2022.106252
日期:2022.9
efficacy with minimum inhibitory concentrations starting from 125 µM. M. kansasii was the most susceptible species. Itaconamides derived from sulfonamides or p-aminosalicylic acid were optimal for activity against extracellular mycobacteria. ICL1 was significantly inhibited by two compounds, with 2-methylene-4-[(4-nitrophenyl)amino]-4-oxobutanoic acid 1k being the most potent (36% inhibition at 10 µM),
需要新的抗分枝杆菌药物,尤其是那些对活跃生长和非复制的分枝杆菌亚群具有双重活性的药物。异柠檬酸裂合酶 (ICL) 是建议的靶点之一,该酶被衣康酸抑制。这就是为什么我们设计和制备了 16 种衣康酸酰胺以及各种苯胺和胺类抗菌药物,以评估它们作为 ICL 的潜在抑制剂和抗分枝杆菌药物的原因。N -Phenylitaconamides 由衣康酸酐和取代的苯胺制备(产率 57-99%)。他们针对分枝杆菌 ICL 和活跃生长的分枝杆菌(结核分枝杆菌H 37 Rv、鸟分枝杆菌、堪萨斯分枝杆菌的两种菌株)进行了表征和评估)。所有衍生物均显示出抗分枝杆菌功效,最低抑制浓度从 125 µM 开始。M. kansasii是最易感的物种。源自磺胺类或对氨基水杨酸的衣康酰胺对细胞外分枝杆菌的活性是最佳的。ICL1 受到两种化合物的显着抑制,其中 2-methylene-4-[(4-nitrophenyl)amino]-4-oxobutanoic